Table 5.
Study | Group of Co-Occurring Users | Outcome | Statistic |
---|---|---|---|
Abrantes, 2009 | Any lifetime cannabis use + lifetime daily tobacco smoker | Adjusted odds ratio of making tobacco smoking quit attempt in the last year | 0.80 |
Abrantes, 2009 | Any lifetime cannabis use + lifetime daily tobacco smoker | Adjusted odds ratio of successfully quitting tobacco in the last year | 0.38* |
Ford, 2002 | Past-month cannabis use (any) + tobacco smoker | Adjusted odds ratio of continued tobacco smoking at 13 years | 1.94* |
Ford, 2002 | Past-month cannabis use (daily for > 2 weeks) + tobacco smoker | Adjusted odds ratio of continued tobacco smoking at 13 years | 3.09 |
Gourlay, 1994 | Past-month cannabis users + tobacco smokers | Unadjusted odds ratio of non-smoking for 28 days prior to week 26 follow-up | 0.4* |
Haskins, 2010 | Daily cannabis users + tobacco smokers | Adjusted odds ratio of quitting smoking during pregnancy | 0.54* |
Haskins, 2010 | Weekly cannabis users + tobacco smokers | Adjusted odds ratio of quitting smoking during pregnancy | 1.00 |
Haskins, 2010 | Monthly cannabis users + tobacco smokers | Adjusted odds ratio of quitting smoking during pregnancy | 0.99 |
Metrik, in press | Weekly cannabis user + tobacco smoker | Adjusted odds ratio of 7-day point prevalence smoking abstinence | 1.13 |
Metrik, in press | Infrequent cannabis user + tobacco smoker | Adjusted odds ratio of 7-day point prevalence smoking abstinence | 0.96 |
Patton, 2005 | Daily cannabis use + cigarette smoking at age 20 | Adjusted odds ratio of no tobacco use in month before age 20 assessment | 0.7 |
Patton, 2005 | Weekly cannabis use + cigarette smoking at age 20 | Adjusted odds ratio of no tobacco use in month before age 20 assessment | 1.0 |
Patton, 2005 | Monthly cannabis use + cigarette smoking at age 20 | Adjusted odds ratio of no tobacco use in month before age 20 assessment | 0.8 |
Stapleton, 2009 | Cannabis use in past 30 days + cigarette smoking | Percent in group with biochemically-verified tobacco abstinence for final 2 weeks of treatment | 40% vs. 55.3%* |
Note. Comparison group for all studies was group of tobacco only smokers. Asterisks indicate that co-occurring users reported significantly poorer outcomes than tobacco only smokers.